Takeda Emphasizes Diversity, Equity, and Inclusion as Essential Elements of Work Culture to bring Equal Opportunities for all at the G20 Summit

Takeda Biopharmaceuticals India Pvt. Ltd. (formerly known as Baxalta Bioscience India Private Limited), a global values-based, R&D-driven biopharmaceutical leader, was invited to a dedicated session on diversity, equity, and inclusion (DE&I) conducted in collaboration with the Healthcare Businesswomen’s Association (HBA) at the G20 Summit. During this session, experts from Takeda and other healthcare organizations discussed strategies for overcoming challenges that hinder advancements in the DE&I space, provided solutions to facilitate substantial transformation, and shared valuable insights on preparing women for careers and achieving gender parity in the continually evolving healthcare industry.

 

Highlighting Takeda’s global stance on DE&I in the forum, Takako Ohyabu, Chief Global Corporate Affairs & Sustainability Officer at Takeda said, “As a global company, we strive to have a workforce as diverse as the talent pools in the communities where we operate and the patients we serve. At Takeda, we are committed to embracing differences, exploring possibilities, and developing our colleagues. We understand that our long-term success depends on building an inclusive environment where all our colleagues are welcomed, empowered, and inspired to use their unique voices and talents. Health equity cannot be achieved without embracing DE&I. This is how we discover innovative approaches to serve our patients, customers, and communities.”

 

Dr. Ruchi Sogarwal, Head of Corporate Affairs at Takeda Biopharmaceuticals India Pvt. Ltd. said, “Furthering our participation in the G20 Health Working Group events, Takeda is honored to contribute to the critical dialogue on DE&I which is essential not only for the society but also for the healthcare industry. Takeda continues to stay committed to the development agenda being led by India through the G20 presidency.”

 

Takeda’s representation at the Equality Lounge at G20 Summit resonates with its objective to catalyze positive change by fostering diversity, equity and inclusion on a global scale. With operations spanning over 80 countries, the company strives to cultivate an environment in which all employees enjoy the opportunity to thrive, develop, and grow based on merit, potential, and aspiration, regardless of background (such as gender, age, nationality, race, religion, belief, disability, sexual orientation, gender identity or lifestyle).

 

About Takeda

Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries.

 

For more information, visit www.takeda.com.

 

Important Notice

For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

 

The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

 

Forward-Looking Statements

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could” “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.

 

Medical information

This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.